QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice

DOI Web Site Web Site PubMed 16 References
  • Aimono Yuka
    Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University Department of Clinical Pharmacy, Hitachi, Ltd., Hitachi General Hospital
  • Kohyama Noriko
    Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University
  • Kamoshida Toshiro
    Department of Medical Gastroenterology, Hitachi, Ltd., Hitachi General Hospital
  • Yamamoto Toshinori
    Showa University Medical Foundation
  • Kogo Mari
    Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University

Bibliographic Information

Other Title
  • 実臨床におけるレジパスビル/ソホスブビル又はシメプレビル/ペグインターフェロン/リバビリン服用中のC型慢性肝炎患者のQOL評価
  • ジツ リンショウ ニ オケル レジパスビル/ソホスブビル マタ ワ シメプレビル/ペグインターフェロン/リバビリン フクヨウ チュウ ノ Cガタ マンセイ カンエン カンジャ ノ QOL ヒョウカ

Search this article

Abstract

<p>Recently, a clinical study using a Chronic Liver Disease Questionnaire (CLDQ) showed that ledipasvir/sofosbuvir (LDV/SOF)-treated patients' QOL was more favorable than that of IFN/ribavirin (RBV)-treated patients. However, no study has reported QOL assessment in clinical practice. In this study, we compared the QOL between patients treated with LDV/SOF and those treated with simeprevir (SMV)/peginterferon (Peg-IFN)/RBV to provide QOL information in clinical practice. The subjects were 169 patients with type I chronic hepatitis C or compensated cirrhosis C (Child-Pugh Grade A) who were treated with SMV/Peg-IFN/RBV or LDV/SOF in Hitachi General Hospital. The QOL was assessed ≥2 weeks after the start of administration using the Japanese version of the CLDQ (Kida et al., 2008 version). The total CLDQ score in the LDV/SOF group was significantly higher than in the SMV/Peg-IFN/RBV group (6.59 vs. 6.38, respectively, p=0.007). In particular, the scores for 4 domains (abdominal symptoms, systemic symptoms, activity, and emotional function) in the former were significantly higher than in the latter (p<0.05). Furthermore, the rates of patients scoring 7 (no symptom) on 8 items in the former were significantly higher than in the latter (p<0.05). In clinical practice, LDV/SOF-treated patients' QOL was more favorable than that of those receiving conventional treatment with IFN and RBV. This study may make it possible for health care professionals to provide clinical QOL information on LDV/SOF therapy to patients. Furthermore, QOL information may promote decision-making for treatment, leading to effective treatment.</p>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 139 (11), 1427-1434, 2019-11-01

    The Pharmaceutical Society of Japan

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top